vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $246.2M, roughly 1.2× HCI Group, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 39.7%, a 56.7% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 9.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
ACAD vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $246.2M |
| Net Profit | $273.6M | $97.7M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 58.5% |
| Net Margin | 96.3% | 39.7% |
| Revenue YoY | 9.4% | 52.1% |
| Net Profit YoY | 90.3% | 3679.2% |
| EPS (diluted) | $1.61 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $246.2M | ||
| Q3 25 | $278.6M | $216.3M | ||
| Q2 25 | $264.6M | $221.9M | ||
| Q1 25 | $244.3M | $216.4M | ||
| Q4 24 | $259.6M | $161.9M | ||
| Q3 24 | $250.4M | $175.3M | ||
| Q2 24 | $242.0M | $206.2M | ||
| Q1 24 | $205.8M | $206.6M |
| Q4 25 | $273.6M | $97.7M | ||
| Q3 25 | $71.8M | $65.5M | ||
| Q2 25 | $26.7M | $66.2M | ||
| Q1 25 | $19.0M | $69.7M | ||
| Q4 24 | $143.7M | $2.6M | ||
| Q3 24 | $32.8M | $5.7M | ||
| Q2 24 | $33.4M | $54.1M | ||
| Q1 24 | $16.6M | $47.6M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 58.5% | ||
| Q3 25 | 12.8% | 41.9% | ||
| Q2 25 | 12.2% | 42.5% | ||
| Q1 25 | 7.9% | 46.4% | ||
| Q4 24 | 59.1% | 3.6% | ||
| Q3 24 | 12.6% | 8.0% | ||
| Q2 24 | 12.6% | 36.9% | ||
| Q1 24 | 7.4% | 37.5% |
| Q4 25 | 96.3% | 39.7% | ||
| Q3 25 | 25.8% | 30.3% | ||
| Q2 25 | 10.1% | 29.8% | ||
| Q1 25 | 7.8% | 32.2% | ||
| Q4 24 | 55.4% | 1.6% | ||
| Q3 24 | 13.1% | 3.2% | ||
| Q2 24 | 13.8% | 26.2% | ||
| Q1 24 | 8.0% | 23.0% |
| Q4 25 | $1.61 | $7.29 | ||
| Q3 25 | $0.42 | $4.90 | ||
| Q2 25 | $0.16 | $5.18 | ||
| Q1 25 | $0.11 | $5.35 | ||
| Q4 24 | $0.86 | $0.32 | ||
| Q3 24 | $0.20 | $0.52 | ||
| Q2 24 | $0.20 | $4.24 | ||
| Q1 24 | $0.10 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.0B |
| Total Assets | $1.6B | $2.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $1.2B | ||
| Q3 25 | $258.0M | $987.9M | ||
| Q2 25 | $253.6M | $947.2M | ||
| Q1 25 | $217.7M | $754.5M | ||
| Q4 24 | $319.6M | $532.5M | ||
| Q3 24 | $155.1M | $518.8M | ||
| Q2 24 | $177.1M | $445.8M | ||
| Q1 24 | $204.7M | $655.4M |
| Q4 25 | $1.2B | $1.0B | ||
| Q3 25 | $917.3M | $821.8M | ||
| Q2 25 | $822.4M | $758.6M | ||
| Q1 25 | $765.2M | $522.7M | ||
| Q4 24 | $732.8M | $453.3M | ||
| Q3 24 | $577.2M | $455.3M | ||
| Q2 24 | $516.7M | $447.3M | ||
| Q1 24 | $464.0M | $395.7M |
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.2B | $2.4B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.2B | $2.2B | ||
| Q3 24 | $976.9M | $2.0B | ||
| Q2 24 | $914.1M | $1.9B | ||
| Q1 24 | $855.1M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $444.4M |
| Free Cash FlowOCF − Capex | — | $440.8M |
| FCF MarginFCF / Revenue | — | 179.0% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | -0.18× | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $444.4M | ||
| Q3 25 | $74.3M | $26.7M | ||
| Q2 25 | $64.0M | $145.0M | ||
| Q1 25 | $20.3M | $162.0M | ||
| Q4 24 | $40.4M | $331.8M | ||
| Q3 24 | $63.2M | $104.1M | ||
| Q2 24 | $25.0M | $-29.0M | ||
| Q1 24 | $29.1M | $182.0M |
| Q4 25 | — | $440.8M | ||
| Q3 25 | $73.9M | $25.9M | ||
| Q2 25 | — | $144.5M | ||
| Q1 25 | — | $160.3M | ||
| Q4 24 | — | $327.8M | ||
| Q3 24 | $63.2M | $103.2M | ||
| Q2 24 | — | $-30.1M | ||
| Q1 24 | — | $181.0M |
| Q4 25 | — | 179.0% | ||
| Q3 25 | 26.5% | 12.0% | ||
| Q2 25 | — | 65.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 202.5% | ||
| Q3 24 | 25.2% | 58.9% | ||
| Q2 24 | — | -14.6% | ||
| Q1 24 | — | 87.6% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 0.1% | 0.4% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | -0.18× | 4.55× | ||
| Q3 25 | 1.03× | 0.41× | ||
| Q2 25 | 2.40× | 2.19× | ||
| Q1 25 | 1.07× | 2.32× | ||
| Q4 24 | 0.28× | 128.41× | ||
| Q3 24 | 1.93× | 18.33× | ||
| Q2 24 | 0.75× | -0.54× | ||
| Q1 24 | 1.76× | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
